The revenue beat and raised EBITDA guidance are positive, but the massive goodwill impairment, declining Adjusted EBITDA margin, and sharply lower free cash flow are significant negatives. The Diabetes Health sale closing in early 2027 will simplify the portfolio but also remove a revenue contributor. Monitor Q4 for further goodwill impairment risk and progress on free cash flow recovery.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $6.28entry
- T+1 · 13d ago +16.40%α +14.75% · $7.31
- T+5 · 7d ago +22.93%α +23.52% · $7.72
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
AdaptHealth reported Q3 2026 revenue of $745.6M (+10.9% YoY), above the $725.9M consensus, but GAAP net loss from continuing operations was $167.0M due to a $184.8M goodwill impairment. Adjusted EBITDA of $141.9M was down 2.9% YoY. The company raised its full-year revenue guidance to $2.88B-$2.90B and Adjusted EBITDA guidance to $510M-$525M, but lowered free cash flow guidance to $50M-$75M. The pending sale of the Diabetes Health business for $235M is on track to close in early 2027.
Key Financial Metrics
Key Facts
- Q3 2026 net revenue $745.6M vs $672.4M YoY, +10.9%
- Organic revenue growth of 12.8%
- GAAP net loss from continuing operations $167.0M vs income of $11.5M YoY, driven by $184.8M goodwill impairment
- Adjusted EBITDA $141.9M vs $146.1M YoY, -2.9%
- Full-year 2026 guidance raised: revenue $2.88B-$2.90B (from $2.85B-$2.89B), Adjusted EBITDA $510M-$525M (from $490M-$520M)
- Free cash flow guidance lowered to $50M-$75M from $80M-$120M
- Pending sale of Diabetes Health business for $235M cash, HSR cleared, closing expected early 2027
- Year-to-date free cash flow $2.6M vs $140.1M in prior year period
Financial Impact
Revenue beat consensus by ~$19.7M (+2.7%); GAAP EPS of -$1.23 from continuing operations vs consensus -$0.06 (miss); Adjusted EBITDA margin contracted to 19.0% from 21.7%
Risk Factors
- Goodwill impairment of $184.8M in Q3 signals potential further write-downs in Respiratory Health and Wellness at Home segments
- Free cash flow guidance cut by ~38% at midpoint suggests ongoing capex intensity and working capital pressure
- Adjusted EBITDA margin declining YoY despite revenue growth indicates cost pressures from the capitated contract ramp
- Pending Diabetes Health sale subject to regulatory approvals and closing conditions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-069116 |
| Document: ahco-20261103.htm | 0001628280-26-069116 |
| Document: 0001628280-26-069116-index-headers.html | 0001628280-26-069116 |
| Document: 0001628280-26-069116-index.html | 0001628280-26-069116 |
| Document: 0001628280-26-069116.txt | 0001628280-26-069116 |
| 8-K Data (Synthetic) | 0001628280-26-069116 |
Track record
20 reports on AHCO
6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +47.49% at T+60 after the Jul 2, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.80 Now $7.73 −0.90% settles Nov 18
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $7.89 Now $7.73 −2.03% settles Nov 17
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $7.87 to $7.66 Now $7.73 −1.78% ▼ −2.67% −2.31% vs SPY
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $7.35 to $7.72 Now $7.73 +5.17% ▲ +5.03% +5.40% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $7.33 to $7.35 Now $7.73 +5.46% ▲ +0.27% −2.09% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $7.41 to $7.33 Now $7.73 +4.32% ▼ −1.08% −1.39% vs SPY
- Nov 3, 202613d ago 8-K Mixed 6/10 Viewing Entry $6.28 to $7.31 Now $7.73 +23.09% ▲ +16.40% +14.75% vs SPY
- Oct 29, 202619d ago Court Ruling Neutral 2/10 Entry $5.81 to $5.91 Now $7.73 +33.05% ▲ +1.72% +2.20% vs SPY
- Oct 13, 20264w ago SC 13G/A Bearish 4/10 Entry $6.33 to $6.25 Now $7.73 −22.12% ▲ +1.26% +0.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers